DermTech Inc DMTK

Primary Symbol: DMTKQ

Healthcare Biotechnology

DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.

OTCPK:DMTKQ - Post by User

DermTech Inc

<< Previous

Bullboard Posts

Next >>

Post by Redrum180on Jul 07, 2021 3:50pm

192 Views

Post# 33506678

DermTech Management Query

A company called Medx on the Venture Exchage claims to have a cheap and effective way of diagnosing skin lesions and detecting melanomas, yet their share price languishes at about .12 CAD and trades in very light volume.

Why wouldn't DermTech at least investigate the possibility of acquiring this company.

Their website is medxhealth.com. If someone is in touch with their management, could they run this by them and possibly provide an answer on this board?

Full disclosure: I am long a modest 15,000 shares of Medx, a tiny percentage of my portfolio.

Thanks in advance for any information you can provide.

<< Previous

Bullboard Posts

Next >>

Catch up with companies that got a Stanley Cup Playoffs boost